Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo de Witte

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
Blood Advances|January 6, 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry studyIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
American Journal of Hematology|April 2, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III studyFrédéric Baron, Fabio Efficace, Laura Cannella, et al.
Nature Communications|April 22, 2017
Clonal evolution in myelodysplastic syndromesPedro da Silva-Coelho, Leonie I Kroeze, Kenichi Yoshida, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Blood|January 19, 2017
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panelTheo de Witte, David Bowen, Marie Robin, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
Blood Advances|January 6, 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry studyIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationLaurent Garderet, Simona Iacobelli, Philippe Moreau, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
American Journal of Hematology|April 2, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III studyFrédéric Baron, Fabio Efficace, Laura Cannella, et al.
Nature Communications|April 22, 2017
Clonal evolution in myelodysplastic syndromesPedro da Silva-Coelho, Leonie I Kroeze, Kenichi Yoshida, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
Blood|January 19, 2017
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panelTheo de Witte, David Bowen, Marie Robin, et al.
Pageof 16